As of June 10, 2025, Immunodiagnostic Systems Holdings PLC (IDH.L) reports a Gross Margin of 4967.60%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Immunodiagnostic Systems Holdings PLC's Gross Margin
Over recent years, Immunodiagnostic Systems Holdings PLC's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2020-03-31 | 4967.60% |
| 2019-03-31 | 43.35% |
| 2018-03-31 | 47.47% |
| 2017-03-31 | 49.77% |
| 2016-03-31 | 58.65% |
This slight downward trend highlights how Immunodiagnostic Systems Holdings PLC manages its operational efficiency and pricing power over time.
Comparing Immunodiagnostic Systems Holdings PLC's Gross Margin to Peers
To better understand Immunodiagnostic Systems Holdings PLC's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Immunodiagnostic Systems Holdings PLC (IDH.L) | 4967.60% |
| Bluelinea SA (ALBLU.PA) | 99.25% |
| Nexstim Oyj (NXTMH.HE) | 95.92% |
| Klea Holding (ALVMG.PA) | 94.24% |
| Biocorp Production SA (ALCOR.PA) | 91.16% |
| Medicalgorithmics SA (MDG.WA) | 84.86% |
Compared to its competitors, Immunodiagnostic Systems Holdings PLC's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.